NextCure, Inc.

DB:2US Stock Report

Market Cap: €32.1m

NextCure Management

Management criteria checks 3/4

NextCure's CEO is Michael Richman, appointed in Oct 2015, has a tenure of 9.08 years. total yearly compensation is $1.04M, comprised of 54.7% salary and 45.3% bonuses, including company stock and options. directly owns 1.45% of the company’s shares, worth €465.40K. The average tenure of the management team and the board of directors is 5.1 years and 4.2 years respectively.

Key information

Michael Richman

Chief executive officer

US$1.0m

Total compensation

CEO salary percentage54.7%
CEO tenure9.1yrs
CEO ownership1.5%
Management average tenure5.1yrs
Board average tenure4.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Michael Richman's remuneration changed compared to NextCure's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$59m

Jun 30 2024n/an/a

-US$61m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$1mUS$572k

-US$63m

Sep 30 2023n/an/a

-US$66m

Jun 30 2023n/an/a

-US$70m

Mar 31 2023n/an/a

-US$70m

Dec 31 2022US$2mUS$549k

-US$75m

Sep 30 2022n/an/a

-US$74m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$73m

Dec 31 2021US$3mUS$529k

-US$69m

Sep 30 2021n/an/a

-US$68m

Jun 30 2021n/an/a

-US$66m

Mar 31 2021n/an/a

-US$63m

Dec 31 2020US$6mUS$491k

-US$37m

Sep 30 2020n/an/a

-US$32m

Jun 30 2020n/an/a

-US$24m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$626kUS$419k

-US$34m

Sep 30 2019n/an/a

-US$30m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$24m

Dec 31 2018US$3mUS$383k

-US$23m

Compensation vs Market: Michael's total compensation ($USD1.04M) is above average for companies of similar size in the German market ($USD472.15K).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.

CEO

Michael Richman (63 yo)

9.1yrs

Tenure

US$1,044,627

Compensation

Mr. Michael S. Richman, MSBA, Co-founded NextCure, Inc. since 2015 and has been its Chief Executive Officer, President & Director since July 2015. Mr. Richman served as the Chief Executive Officer and Pres...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Richman
Co-Founder9.1yrsUS$1.04m1.45%
€ 465.4k
Solomon Langermann
Chief Scientific Officer5.9yrsUS$681.59k0.13%
€ 42.8k
Lieping Chen
Co-Founder & Chairman of Scientific Advisory Board9.8yrsno datano data
Steven Cobourn
Chief Financial Officer6.8yrsUS$1.01mno data
Timothy Mayer
Chief Operating Officer5.1yrsno datano data
Kevin Shaw
Senior VP & General Counsel2.5yrsno datano data
Sourav Kundu
Senior Vice President of Development & Manufacturing3.3yrsno datano data
Sebastien Maloveste
Senior Vice President of Business Development1.3yrsno datano data
Udayan Guha
Senior Vice President of Clinical & Translational Development1.3yrsno datano data

5.1yrs

Average Tenure

63yo

Average Age

Experienced Management: 2US's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michael Richman
Co-Founder9.1yrsUS$1.04m1.45%
€ 465.4k
Lieping Chen
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Elaine Jones
Independent Director8.9yrsUS$67.47k0%
€ 0
Mario Sznol
Member of Scientific Advisory Boardno datano datano data
David Kabakoff
Independent Chairman of the Board8.9yrsUS$93.16k0.22%
€ 71.3k
Stephen Webster
Independent Director5.6yrsUS$71.66k0%
€ 0
Ellen Feigal
Independent Director3.1yrsUS$61.66k0%
€ 0
Stephen Miller
Member of Scientific Advisory Boardno datano datano data
John Houston
Independent Director4.2yrsUS$61.66k0%
€ 0
Weiping Zou
Member of Scientific Advisory Board3.1yrsno datano data
Ursula Matulonis
Member of Scientific Advisory Board3.1yrsno datano data
Anne Borgman-Hagey
Independent Director3.1yrsUS$60.66k0%
€ 0

4.2yrs

Average Tenure

66yo

Average Age

Experienced Board: 2US's board of directors are considered experienced (4.2 years average tenure).